The newly secured funds will be directed toward expanding Supira’s clinical programmes focussed on high-risk percutaneous coronary intervention (HRPCI) and cardiogenic shock (CS)

Supira Medical has completed an oversubscribed Series E financing round, raising $120 million to accelerate its mission of transforming the percutaneous ventricular assist device (pVAD) market. The funding round was led by new investors Novo Holdings and Qatar Investment Authority (QIA), with additional participation from two undisclosed strategic investors. Existing investors, including Cormorant Asset Management, The Capital Partnership (TCP), 415 Capital, AMED Ventures, PA MedTech VC Fund and Unorthodox Ventures, also contributed to the round.

Expanding Clinical Programmes for HRPCI and Cardiogenic Shock

The newly secured funds will be directed toward expanding Supira’s clinical programmes focussed on high-risk percutaneous coronary intervention (HRPCI) and cardiogenic shock (CS). This includes the SUPPORT II U.S. Pivotal Study for HRPCI, a critical step toward securing FDA premarket approval (PMA) for the company’s pVAD technology.

As per Medical Buyer report, experts emphasize the increasing demand for advanced ventricular support devices to improve clinical outcomes for patients undergoing HRPCI and those affected by cardiogenic shock. Supira Medical’s low-profile, high-flow technology platform is designed to enhance myocardial recovery and peripheral organ perfusion in these high-risk patient groups.

Progress in Clinical Studies

Further strengthening its clinical foundation, Supira Medical recently completed enrollment for the U.S. SUPPORT I Early Feasibility Study (EFS). This prospective, single-arm study evaluated the safety and feasibility of Supira’s pVAD in 15 patients across four clinical sites.

According to Medical Buyer, pVADs play a crucial role in maintaining cardiovascular function during HRPCI, especially for patients with complex coronary anatomy, hemodynamic instability and multiple comorbidities. They are also used in cases of cardiogenic shock—a life-threatening condition where the heart struggles to pump enough blood to sustain vital organs, typically due to a heart attack or heart failure.

Strategic Growth and Future Outlook

As part of its continued growth, Supira Medical has also strengthened its leadership with the addition of a new board member. Experts believe this strategic move will further reinforce the company’s efforts in bringing next-generation pVAD technology closer to commercialization.

As highlighted by Medical Buyer, the Supira System remains an investigational device and is not yet approved for sale in the U.S. or globally.

Piper Sandler served as the exclusive financial advisor for the transaction, while Sidley Austin acted as legal counsel.